(NASDAQ: DARE) Dare Bioscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Dare Bioscience's revenue in 2025 is -$17,701.On average, 2 Wall Street analysts forecast DARE's revenue for 2025 to be $13,439,063, with the lowest DARE revenue forecast at $53,918, and the highest DARE revenue forecast at $26,824,209. On average, 1 Wall Street analysts forecast DARE's revenue for 2026 to be $769,949,154, with the lowest DARE revenue forecast at $769,949,154, and the highest DARE revenue forecast at $769,949,154.
In 2027, DARE is forecast to generate $1,270,443,064 in revenue, with the lowest revenue forecast at $1,270,443,064 and the highest revenue forecast at $1,270,443,064.